Bianca Y. Kang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bianca Y. Kang has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Murad Alam
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
9 shared publications - Emily Poon
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
5 shared publications - Sarah A. Ibrahim
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, USA
5 shared publications Arisa Ortiz
Department of Dermatology, University of California San Diego, San Diego, USA
2 shared publicationsBrandon Worley
Florida Dermatology and Skin Cancer Centers, Lake Wales, Florida
2 shared publications- Edward Victor Ross
Scripps Clinic San Diego California USA
2 shared publications
Latest Publications
- 23 July 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
Tumor Characteristics, Subclinical Extent, and Time to Poor Outcomes for less Common Skin Cancers
BACKGROUND: The growth pattern and response to treatment of rare tumors are poorly understood. OBJECTIVE: To describe patient and tumor characteristics, including extent of subclinical spread and time to poor outcomes, for uncommon nonmelanoma skin cancer tumors. MATERIALS AND METHODS: PubMed and MEDLINE databases were searched for original reports of relevant tumors from January 1950 to November 2022. Review articles and reports of tumors that were previously reported or treated without margin clearance were excluded. RESULTS: Data from 347 reports were extracted. Most tumors were primary, on the head and neck, and in older individuals (except dermatofibrosarcoma protuberans). Subclinical tumor extent was greater than 3 for all types, with largest postoperative defect sizes for dermatofibrosarcoma protuberans and extramammary Paget disease. Poor outcomes occurred in greater than 20% of extramammary Paget disease and Merkel cell carcinoma cases and 10% of atypical fibroxanthoma cases. Mean times to poor outcomes ranged from 33 to 122 months, with atypical fibroxanthoma having the shortest times and sebaceous carcinoma the longest. CONCLUSION: The subclinical extent of rare tumors varies. Although disease-related mortality was rare, poor outcomes, defined to include also recurrence and metastasis, were more common. The information for time to poor outcomes may guide follow-up schedules.
- 23 July 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
Tumor Characteristics, Subclinical Extent, and Time to Poor Outcomes for less Common Skin Cancers
BACKGROUND: The growth pattern and response to treatment of rare tumors are poorly understood. OBJECTIVE: To describe patient and tumor characteristics, including extent of subclinical spread and time to poor outcomes, for uncommon nonmelanoma skin cancer tumors. MATERIALS AND METHODS: PubMed and MEDLINE databases were searched for original reports of relevant tumors from January 1950 to November 2022. Review articles and reports of tumors that were previously reported or treated without margin clearance were excluded. RESULTS: Data from 347 reports were extracted. Most tumors were primary, on the head and neck, and in older individuals (except dermatofibrosarcoma protuberans). Subclinical tumor extent was greater than 3 for all types, with largest postoperative defect sizes for dermatofibrosarcoma protuberans and extramammary Paget disease. Poor outcomes occurred in greater than 20% of extramammary Paget disease and Merkel cell carcinoma cases and 10% of atypical fibroxanthoma cases. Mean times to poor outcomes ranged from 33 to 122 months, with atypical fibroxanthoma having the shortest times and sebaceous carcinoma the longest. CONCLUSION: The subclinical extent of rare tumors varies. Although disease-related mortality was rare, poor outcomes, defined to include also recurrence and metastasis, were more common. The information for time to poor outcomes may guide follow-up schedules.
- 7 July 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 52 (10) , e156-e158
Comparative Efficacy of Topical Anesthetic Compounds Prior to 1927-nm Fractional Thulium Fiber Laser
Was not provided for this article.
- 7 July 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 52 (10) , e156-e158
Comparative Efficacy of Topical Anesthetic Compounds Prior to 1927-nm Fractional Thulium Fiber Laser
Was not provided for this article.
- Open Access
- 13 April 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (4) , e70798
Assessing the Utility of a Cosmetic Dermatology Journal Club
Background: Journal clubs provide opportunities for discussion of new and evolving practices and technologies. Objective: We sought to evaluate the utility and effectiveness of a monthly web‐based cosmetic dermatology journal club facilitated by faculty, residents, and medical students. Results: From May 2025 to September 2025, 16 articles were discussed and 41 responses were recorded (response rate: 60%). Most respondents found the journal club was an appropriate length, engaging, and very useful. Relevance, frequency, and likelihood to participate in the future varied significantly by participant type. Medical students and residents collectively considered the journal club too infrequent ( p = 0.03) and reported it had less relevance to their practice ( p < 0.001). Conclusion: A monthly web‐based cosmetic dermatology journal club was generally positively received by respondents.
- 13 April 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (4) , e70798
Open AccessAssessing the Utility of a Cosmetic Dermatology Journal Club
Background: Journal clubs provide opportunities for discussion of new and evolving practices and technologies. Objective: We sought to evaluate the utility and effectiveness of a monthly web‐based cosmetic dermatology journal club facilitated by faculty, residents, and medical students. Results: From May 2025 to September 2025, 16 articles were discussed and 41 responses were recorded (response rate: 60%). Most respondents found the journal club was an appropriate length, engaging, and very useful. Relevance, frequency, and likelihood to participate in the future varied significantly by participant type. Medical students and residents collectively considered the journal club too infrequent ( p = 0.03) and reported it had less relevance to their practice ( p < 0.001). Conclusion: A monthly web‐based cosmetic dermatology journal club was generally positively received by respondents.
- 17 October 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-4
Compensation models in academic cosmetic dermatology
- 17 October 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-4
Compensation models in academic cosmetic dermatology
- Open Access
- 9 August 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (8) , e70385
Prevention of Calcium Hydroxyapatite Nodules in the Neck With Use of Botulinum Toxin: A Case Report and Review of Anatomy and Pathophysiology
Background: Calcium hydroxylapatite (CaHA) is a biostimulatory filler frequently used in a hyperdilute form to improve skin quality. While generally safe, nodule formation is the most common adverse event, particularly in dynamic areas.Aims: To describe a case of delayed‐onset CaHA nodules in the neck and review anatomical and procedural factors contributing to this complication, as well as prevention and management strategies.Patient: A 72‐year‐old woman underwent three sessions of hyperdilute CaHA injections to the neck, with recent or concurrent onabotulinumtoxinA injections. After the third treatment, which followed a longer interval since her last botulinum toxin injection, she developed multiple firm, non‐tender nodules. A stepwise approach with intralesional saline injections—initially using needles and later a cannula—was implemented.Results: Initial saline injections with small‐gauge needles yielded minimal improvement. Transitioning to a 22G cannula enabled both saline delivery and mechanical disruption, resulting in complete resolution after five total treatments. The patient has remained recurrence‐free for over 2 years.Conclusions: Nodule formation following CaHA injection is most often due to product aggregation, and is particularly common in dynamic areas with thin overlying skin. Combining treatment with botulinum toxin may reduce this risk by limiting movement. Other preventive strategies include using higher dilutions of CaHA, avoiding high‐risk areas, and optimizing injection depth. When nodules do occur, mechanical disruption with a cannula combined with saline injection is a safe, effective, and minimally invasive first‐line treatment.
- 9 August 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (8) , e70385
Open AccessPrevention of Calcium Hydroxyapatite Nodules in the Neck With Use of Botulinum Toxin: A Case Report and Review of Anatomy and Pathophysiology
Background: Calcium hydroxylapatite (CaHA) is a biostimulatory filler frequently used in a hyperdilute form to improve skin quality. While generally safe, nodule formation is the most common adverse event, particularly in dynamic areas.Aims: To describe a case of delayed‐onset CaHA nodules in the neck and review anatomical and procedural factors contributing to this complication, as well as prevention and management strategies.Patient: A 72‐year‐old woman underwent three sessions of hyperdilute CaHA injections to the neck, with recent or concurrent onabotulinumtoxinA injections. After the third treatment, which followed a longer interval since her last botulinum toxin injection, she developed multiple firm, non‐tender nodules. A stepwise approach with intralesional saline injections—initially using needles and later a cannula—was implemented.Results: Initial saline injections with small‐gauge needles yielded minimal improvement. Transitioning to a 22G cannula enabled both saline delivery and mechanical disruption, resulting in complete resolution after five total treatments. The patient has remained recurrence‐free for over 2 years.Conclusions: Nodule formation following CaHA injection is most often due to product aggregation, and is particularly common in dynamic areas with thin overlying skin. Combining treatment with botulinum toxin may reduce this risk by limiting movement. Other preventive strategies include using higher dilutions of CaHA, avoiding high‐risk areas, and optimizing injection depth. When nodules do occur, mechanical disruption with a cannula combined with saline injection is a safe, effective, and minimally invasive first‐line treatment.
- 11 June 2025
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 57 (6) , 477-489
Consensus Statement on the Prevention and Management of Complications of Fully Ablative Laser Resurfacing of the Face
Objectives: To achieve consensus among expert laser surgeons on standards for the prevention and management of adverse events from fully ablative laser resurfacing of the face.Materials and Methods: Delphi study with two rounds of ratings and revisions until consensus was achieved. The draft set of statements was developed by a steering committee based on expert clinical experience. This was followed by two rounds of rating and revisions completed by an expert panel, then a virtual consensus meeting. In both rounds, respondents rated the draft statements on a 9‐point Likert scale (1 = strongly disagree; 9 = strongly agree) and optionally provided comments. The consensus meeting was supplemented by the results of a systematic review of the literature (from 2000 to 2023).Results: Two rounds of Delphi survey were completed by 34 participants across four countries. Represented specialties were dermatology, facial plastic surgery, plastic surgery, and oculoplastic surgery. The initial 105 statements from round 1 expanded to 112 in round 2, with 96 statements achieving consensus. These included possible adverse events (11 statements); absolute and relative contraindications to treatment (5 statements); preoperative care and antimicrobial prophylaxis precautions (16 statements); intraoperative precautions (17 statements); postoperative care (21 statements); monitoring for and management of infection (16 statements); management of pigmentation changes (6 statements); and management of scarring and incipient scarring (4 statements).Conclusion: An international consensus statement was developed for the prevention and management of complications associated with fully ablative laser resurfacing of the face. While expert practices vary, key factors for optimizing outcomes include careful patient selection, counseling, and meticulous pre‐ and postoperative care. Further research will improve our understanding of this treatment technique.
- 11 June 2025
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 57 (6) , 477-489
Consensus Statement on the Prevention and Management of Complications of Fully Ablative Laser Resurfacing of the Face
Objectives: To achieve consensus among expert laser surgeons on standards for the prevention and management of adverse events from fully ablative laser resurfacing of the face.Materials and Methods: Delphi study with two rounds of ratings and revisions until consensus was achieved. The draft set of statements was developed by a steering committee based on expert clinical experience. This was followed by two rounds of rating and revisions completed by an expert panel, then a virtual consensus meeting. In both rounds, respondents rated the draft statements on a 9‐point Likert scale (1 = strongly disagree; 9 = strongly agree) and optionally provided comments. The consensus meeting was supplemented by the results of a systematic review of the literature (from 2000 to 2023).Results: Two rounds of Delphi survey were completed by 34 participants across four countries. Represented specialties were dermatology, facial plastic surgery, plastic surgery, and oculoplastic surgery. The initial 105 statements from round 1 expanded to 112 in round 2, with 96 statements achieving consensus. These included possible adverse events (11 statements); absolute and relative contraindications to treatment (5 statements); preoperative care and antimicrobial prophylaxis precautions (16 statements); intraoperative precautions (17 statements); postoperative care (21 statements); monitoring for and management of infection (16 statements); management of pigmentation changes (6 statements); and management of scarring and incipient scarring (4 statements).Conclusion: An international consensus statement was developed for the prevention and management of complications associated with fully ablative laser resurfacing of the face. While expert practices vary, key factors for optimizing outcomes include careful patient selection, counseling, and meticulous pre‐ and postoperative care. Further research will improve our understanding of this treatment technique.
- 5 December 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (2) , 379-381
Umbilical nodule present since birth
- 5 December 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (2) , 379-381
Umbilical nodule present since birth
- Open Access
- 1 October 2022
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 158 (10) , 1193-1201
Evidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery
Importance: Laser-assisted drug delivery (LADD) is used for various medical and cosmetic applications. However, there is insufficient evidence-based guidance to assist clinicians performing LADD.Objective: To develop recommendations for the safe and effective use of LADD.Evidence Review: A systematic literature review of Cochrane Central Register of Controlled Trials, Embase, and MEDLINE was conducted in December 2019 to identify publications reporting research on LADD. A multidisciplinary panel was convened to draft recommendations informed by the systematic review; they were refined through 2 rounds of Delphi survey, 2 consensus meetings, and iterative review by all panelists until unanimous consensus was achieved.Findings: Of the 48 published studies of ablative fractional LADD that met inclusion criteria, 4 were cosmetic studies; 21, oncologic; and 23, medical (not cosmetic/oncologic), and 6 publications of nonablative fractional LADD were included at the request of the expert panel, producing a total of 54 studies. Thirty-four studies (63.0%) were deemed to have low risk of bias, 17 studies (31.5%) had moderate risk, and 3 (5.5%) had serious risk. The key findings that informed the guidelines developed by the expert panel were as follows: LADD is safe in adults and adolescents (≥12 years) with all Fitzpatrick skin types and in patients with immunosuppression; it is an effective treatment for actinic keratosis, cutaneous squamous cell carcinoma in situ, actinic cheilitis, hypertrophic scars, and keloids; it is useful for epidermal and dermal analgesia; drug delivery may be increased through the application of heat, pressure, or occlusion, or by using an aqueous drug solution; laser settings should be selected to ensure that channel diameter is greater than the delivered molecule; antibiotic prophylaxis is not recommended, except with impaired wound healing; antiviral prophylaxis is recommended when treating the face and genitalia; and antifungal prophylaxis is not recommended. The guideline’s 15 recommendations address 5 areas of LADD use: (I) indications and contraindications; (II) parameters to report; (III) optimization of drug delivery; (IV) safety considerations; and (V) prophylaxis for bacterial, viral, and fungal infections.Conclusions and Relevance: This systematic review and Delphi consensus approach culminated in an evidence-based clinical practice guideline for safe and effective use of LADD in a variety of applications. Future research will further improve our understanding of this novel treatment technique.
- 1 October 2022
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 158 (10) , 1193-1201
Open AccessEvidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery
Importance: Laser-assisted drug delivery (LADD) is used for various medical and cosmetic applications. However, there is insufficient evidence-based guidance to assist clinicians performing LADD.Objective: To develop recommendations for the safe and effective use of LADD.Evidence Review: A systematic literature review of Cochrane Central Register of Controlled Trials, Embase, and MEDLINE was conducted in December 2019 to identify publications reporting research on LADD. A multidisciplinary panel was convened to draft recommendations informed by the systematic review; they were refined through 2 rounds of Delphi survey, 2 consensus meetings, and iterative review by all panelists until unanimous consensus was achieved.Findings: Of the 48 published studies of ablative fractional LADD that met inclusion criteria, 4 were cosmetic studies; 21, oncologic; and 23, medical (not cosmetic/oncologic), and 6 publications of nonablative fractional LADD were included at the request of the expert panel, producing a total of 54 studies. Thirty-four studies (63.0%) were deemed to have low risk of bias, 17 studies (31.5%) had moderate risk, and 3 (5.5%) had serious risk. The key findings that informed the guidelines developed by the expert panel were as follows: LADD is safe in adults and adolescents (≥12 years) with all Fitzpatrick skin types and in patients with immunosuppression; it is an effective treatment for actinic keratosis, cutaneous squamous cell carcinoma in situ, actinic cheilitis, hypertrophic scars, and keloids; it is useful for epidermal and dermal analgesia; drug delivery may be increased through the application of heat, pressure, or occlusion, or by using an aqueous drug solution; laser settings should be selected to ensure that channel diameter is greater than the delivered molecule; antibiotic prophylaxis is not recommended, except with impaired wound healing; antiviral prophylaxis is recommended when treating the face and genitalia; and antifungal prophylaxis is not recommended. The guideline’s 15 recommendations address 5 areas of LADD use: (I) indications and contraindications; (II) parameters to report; (III) optimization of drug delivery; (IV) safety considerations; and (V) prophylaxis for bacterial, viral, and fungal infections.Conclusions and Relevance: This systematic review and Delphi consensus approach culminated in an evidence-based clinical practice guideline for safe and effective use of LADD in a variety of applications. Future research will further improve our understanding of this novel treatment technique.
- 1 April 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 144, 8-15
A memorandum of understanding has facilitated guideline development involving collaborating groups
- 1 April 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 144, 8-15
A memorandum of understanding has facilitated guideline development involving collaborating groups
- 21 December 2021
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (2) , 867-868
Guidelines of care in cosmetic dermatology: From customized treatment for few to evidence‐based treatments for many
- 21 December 2021
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (2) , 867-868
Guidelines of care in cosmetic dermatology: From customized treatment for few to evidence‐based treatments for many